Reportstack

US Breast Cancer Drug Pipeline Analysis

 

Naperville, IL -- (ReleaseWire) -- 05/30/2014 -- Reportstack, provider of premium market research reports announces the addition of US Breast Cancer Drug Pipeline Analysis market report to its offering
The pharmaceutical companies have recently been focusing increasingly on women's health. Among the diseases specific to women, breast cancer has become one of the leading causes of death for the women population globally and accounts for almost 3 per cent of the causes of death in women. It has been estimated that one in every 12 women is most likely to develop breast cancer at some point in her life, owing to risk factors such as hormonal effects, age and genetic predisposition. According to the American Cancer Society (ACS), the cases of women with breast cancer accounts to more than 1 in 4 cancer patients in the US. It is further estimated that in 2013, close to 32,000 new cases of breast cancer are expected to be diagnosed and close to 40,000 people are expected to die from breast cancer. By 2020, the combined sales of emerging and new therapies would account for more than 25% of the overall market for breast cancer drug treatments.

US Breast Cancer Drug Pipeline Analysis by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Breast Cancer. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Breast Cancer drug market based upon development process. Following parameters for each drug profile in development phase are covered in US Breast Cancer Drug Pipeline Analysis research report:

Drug Profile Overview

Alternate Names for Drug

Active Indication

Phase of Development

Mechanism of Action

Brand Name

Patent Information

Country for Clinical Trial

Owner / Originator/ Licensee/Collaborator

Administrative Route

Drug Class

ATC Codes

US Breast Cancer Drug Pipeline by Clinical Phase:

Research: 9

Preclinical: 43

Phase-I: 33

Phase-I/II: 19

Phase-II: 73

Phase-II/III: 2

Phase-III: 12

Registered: 3

Marketed: 28

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/156614/us-breast-cancer-drug-pipeline-analysis.html
Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###